EMulate Therapeutics Announces the Publication of the Evaluation of Its Ultra-Low Radiofrequency Energy Device in Murine Model of Glioblastoma in BMC Bioelectric Medicine


BELLEVUE, Wash.--(BUSINESS WIRE)-- EMulate Therapeutics, Inc. (EMulate) announces the peer-reviewed publication titled, “Evaluation of the EMulate Therapeutics’ Ultra-Low Radiofrequency Energy (ulRFE®) Device in Murine Model of Glioblastoma (GBM)” in BMC Bioelectronic Medicine. The authors of the paper (Rajesh Mukthavaram; Pengfei Jiang; Sandra Pastorino; Natsuko Nomura; Feng Lin; Santosh Kesari) tested the effectiveness of the emulation of EMulate’s ulRFE signal of paclitaxel (A1A) and the immune checkpoint inhibitor ulRFE signal targeting immune checkpoints CTLA-4 and PD-1 (A2) in a murine GBM model.

“These data are encouraging as they demonstrate the effects we have measured and observed in human feasibility trials (NCT02296580 and NCT02507102) and other pre-clinical studies in glioblastoma models,” said Chris Rivera, EMulate’s CEO. “This independent study by the Kesari Laboratory (Pacific Neuroscience Institute, Providence Southern California) further displays the encouraging clinical activity in patients afflicted with GBM that has been observed and recently published and supports that our A1A ulRFE signal emulates the mechanism of the taxane paclitaxel. Furthermore, a novel A2 signal targeting the immune function in mice and humans is available for testing in future clinical trials.”

Dr. Santosh Kesari, the principal investigator in the study, added, “The novelty of the technology may surprise many practitioners in the field of oncology but the effectiveness we see in animal models and human trials in my view indicates great potential as a new tool to fight the scourge of glioblastoma.”

Mr. Rivera concluded, “EMulate is also seeking to initiate a pivotal Phase III study in newly diagnosed GBM in the future and is also seeking FDA approval for treatment of diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), via the Humanitarian Device Exemption pathway later this year based on encouraging compassionate use results in patients as well as encouraging pre-clinical study results in DIPG animal models. We are planning to initiate a pivotal Phase III study in these indications in 2024.”

About EMulate Therapeutics, Inc.

EMulate Therapeutics is a clinical stage company utilizing its proprietary radio frequency energy technology (RFE) targeted at the low and ultra-low ends of the RFE spectrum (ulRFE®) to provide safe and effective therapeutic benefits specifically targeted at patients’ underlying conditions. The company has generated encouraging human data from patients afflicted with glioblastoma and diffuse midline glioma and is preparing for pivotal (phase III) studies in each indication. It has also generated encouraging preclinical studies in pain management and mental health models and is preparing for initial human clinical trials in each area. In addition, positive data have been generated independently in animal health (positive cancer results in over 20 different solid tumor types in canines (pets)), as well as in bio-agriculture models. EMulate Therapeutics is the licensor of its proprietary technology to Hapbee Technologies, Inc. (HAPB: TSVX). Hapbee is a commercial stage consumer wellness-wearable technology company spun out from EMulate in 2019. EMulate is the largest independent shareholder in Hapbee and recipient of quarterly royalties from net sales.

About our ulRFE Device

EMulate Therapeutics (EMTx) has developed a non-sterile, non-invasive, non-thermal, non-ionizing, battery-powered, portable investigational medical device that uses low to ultra-low level (DC-22kHz) frequencies to deliver specific electromagnetic fields to produce specific biological effects, including, e.g., increasing tubulin polymerization in numerous cancer models, emulating the effects of psychedelic drugs in mental health models and reducing pain sensations, among others. The system emits a low power magnetic field (< 100 mG) that can be applied locally or globally, dependent on the type of therapeutic effect sought. The EMTX signals are stored as WAV files on the device and emitted via a cable to the attached antenna unit.


This press release contains “forward-looking statements.” Forward-looking statements discuss matters that are not historical facts. Because they discuss future events or conditions, forward-looking statements may include words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “could,” “should,” “would,” “plan,” “project,” “forecast,” “seek,” “near future,” and “potential,” the negatives thereof or similar expressions. Forward-looking statements speak only as of the date made, are based on various underlying assumptions and current expectations about the future and are not guarantees of future performance. While we believe these assumptions and expectations are reasonable, are made in good faith and have a reasonable basis, assumed facts or bases almost always vary from actual results, and the differences between assumed facts or expectations and actual results can be material, depending on the circumstances. Such statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, level of activity, performance or achievement to be materially different from the results of operations or plans expressed or implied by such forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates, or to regard them as representations that the results or conditions described in such statements will occur or that our objectives and plans will be achieved.

Except to the extent required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, a change in events, conditions, circumstances or assumptions underlying such statements, or otherwise.


Kyle J. Kingma


Source: EMulate Therapeutics, Inc.

Back to news